Anondita Medicare IPO Listing: Stock lists at 90% premium on NSE SME

Anondita Medicare IPO Listing: ‘Cobra’ Condoms Maker Makes a Grand Entry with 90% Premium on NSE SME

Anondita Medicare, the manufacturer of the popular ‘Cobra’ brand of flavored male condoms, made a remarkable debut on the NSE SME platform today.

Its shares, issued at ₹145 in the IPO, were listed at ₹275.50, offering a listing premium of 90% to investors.

This strong debut further reinforces investor confidence in niche healthcare companies tapping into underserved or high-growth product categories.

The stock didn’t just stop at listing gains—it rallied further to hit the upper circuit at ₹289.25 and closed at that level, delivering nearly 100% gains on day one of trade.

Blockbuster IPO: 300x Oversubscription Signals Massive Demand

Anondita Medicare’s ₹69.50 crore initial public offering (IPO) was open for subscription from August 22 to August 26, 2025, and the response was nothing short of extraordinary.

The IPO saw an overall subscription of 300.89 times, indicating significant investor enthusiasm across all categories.

Here’s how the investor categories fared:

• Qualified Institutional Buyers (QIBs): Subscribed 153.03 times (excluding anchor portion)
• Non-Institutional Investors (NIIs): Subscribed 531.82 times
• Retail Individual Investors (RIIs): Subscribed 286.20 times

The sheer magnitude of bids demonstrates strong faith in Anondita Medicare’s business model, future prospects, and the growing potential of India’s sexual wellness and healthcare markets.

Use of Funds: Strategic Allocation for Growth

Anondita’s IPO proceeds of ₹69.50 crore will be used to support its expansion plans, including:

• ₹6 crore: Purchase of new equipment and machinery to increase production capacity
• ₹35 crore: Working capital requirements to support growing operations and exports
• Remaining funds: Strategic acquisitions, brand-building, and general corporate purposes

This fund allocation suggests a well-thought-out plan that focuses on both operational scaling and long-term brand consolidation in domestic and international markets.

Company Overview: Who is Anondita Medicare?

Established in March 2024, Anondita Medicare is a relatively young entrant in the healthcare space but has made a name for itself quickly with its flagship product—Cobra brand flavored male condoms.

Key Facts About the Company:

• Annual Production Capacity: 56.2 crore (562 million) condoms
• Manufacturing Base: Noida, Uttar Pradesh
• Export Markets: Southeast Asia, Africa, and the Middle East
• Social Outreach: Collaborates with international NGOs, health organizations, and government agencies to promote family planning, public health, and sexual wellness

Unlike legacy players, Anondita Medicare has adopted a modern branding approach, tapping into youth-centric, flavor-focused, and fun-based marketing to differentiate itself in a traditionally taboo market segment.

Financial Performance: Robust Growth, Rising Debt

Despite being a new player, Anondita Medicare has posted strong financial performance in its initial years, reflecting growing demand and aggressive market penetration.

Profitability:

• FY 2023: Net profit of ₹35 lakh
• FY 2024: Net profit jumped to ₹3.84 crore
• FY 2025: Net profit surged further to ₹16.42 crore

This exponential increase in profitability suggests solid margin expansion and operational efficiencies.

Revenue Growth:

• The company’s total income grew at a Compound Annual Growth Rate (CAGR) of over 46%, reaching ₹77.13 crore in FY 2025.
• Such growth is exceptional for a newly established company and is indicative of a rapidly growing market and effective business execution.

Rising Debt:

However, this rapid growth has come at the cost of increasing debt:

• FY 2023: ₹22.66 crore
• FY 2024: ₹24.01 crore
• FY 2025: ₹27.39 crore

While the company’s debt is rising in line with its expansion, it’s important for investors to watch how efficiently Anondita deploys the IPO proceeds to reduce leverage, boost cash flow, and maintain healthy interest coverage ratios.

Market Opportunity: Tapping Into a Growing Industry

India’s sexual wellness industry is witnessing a transformation. What was once a hush-hush topic is increasingly gaining mainstream attention, particularly among younger, urban consumers.

Increased awareness around sexual health, family planning, and safe sex practices, along with government and NGO initiatives, are contributing to the sector’s formalization.

The Indian condom market alone is expected to grow at a CAGR of over 8-10% over the next five years, driven by:

• Rising awareness and sex education
• Changing social attitudes among youth
• Government and NGO initiatives
• Increasing demand for premium and flavored variants

With its export footprint already established and an aggressive domestic marketing strategy in place, Anondita Medicare is well-positioned to ride this wave.

IPO Valuation: Was It Justified?

At an issue price of ₹145 per share, Anondita’s IPO appeared reasonably priced considering its revenue trajectory and market opportunity.

The nearly 100% premium on listing day may seem aggressive, but given the company’s fundamentals and market sentiment, it reflects investor expectations for future growth.

However, such high demand and price momentum often come with short-term volatility. Retail investors must understand that SME IPOs can be illiquid and price movements sharper than on the main board.

Final Thoughts: A Strong Debut, But Eyes on Execution

Anondita Medicare’s IPO success story is a strong testament to investor appetite for growth-oriented healthcare startups, particularly those operating in emerging or previously under-served segments like male sexual wellness.

Its impressive listing and robust oversubscription figures show that the market sees real potential.

However, the path ahead involves prudent financial management, brand positioning, and efficient capital utilization. Execution risk remains high, especially for a young company scaling up at such a rapid pace.

For investors, the IPO gains may be encouraging, but long-term performance will depend on consistent profitability, debt management, and expansion into newer markets.

If Anondita delivers on these fronts, it may just become one of the most promising SME success stories in India’s healthcare sector.